New Project Will Enable Rapid Detection of Staphylococcus Bacteria & Create a New Bio-based Disinfectant to Reduce Hospital-acquired Infections

The developments will be tested at Hospital General Universitario de Valencia, which participates in the NOSOSENS project through its research foundation, together with AIMPLAS, Química Deambla-Rogemar, Crespo Printing Group and Assessoria de Gestió i Comunicacions (AGC). The aim of these new solutions is to reduce deaths caused by drug-resistant infections acquired in hospital settings, which could reach 10 million worldwide by 2050.

According to data from the European Centre for Disease Prevention and Control, approximately 4 million patients acquire a healthcare-associated infection (HAI) or nosocomial infection each year in the European Union and approximately 37,000 deaths are the direct result of these infections, making them a major cause of mortality. Infectious microorganisms acquired in hospitals are often resistant to many common antibiotics. By 2050, the number of deaths caused by drug-resistant infections is expected to increase to 10 million worldwide, thus posing a serious public health problem.

Early detection of nosocomial infections and effective disinfection of hospitals and healthcare centres are key to reducing these figures, but the methods currently used have their limitations. Hence the creation of the NOSOSENS Project, which is working on a new bio-based disinfectant designed to eliminate the main pathogens on a new, flexible and portable biosensor platform. It uses printed electrochemical sensors for rapid, selective detection of Staphylococcus aureus, which is resistant to methicillin and responsible for 11% of nosocomial infections.

The Fundación de Investigación Hospital General Universitario de Valencia, the Plastics Technology Centre (AIMPLAS), the companies Química Deambla-Rogemar and Crespo Printing Group, coordinated by the Assessoria de Gestió y Comunicacions (AGC), are collaborating on this research project funded by the Valencian Institute for Competitiveness and Innovation (IVACE+i) through the call for Strategic Projects in Cooperation 2023 of the Valencian Innovation Agency in conjunction with the ERDF Programme.

Immediate test and environmentally friendly disinfectant

The diagnostic method par excellence currently used in hospitals for the prevention of nosocomial diseases involves the detection of pathogens by means of cell culture microscopy on a monthly basis. The results become available in four to five days on average. The new portable electrochemical biosensor platform from NOSOSENS provides immediate specific detection and quantification of bacteria from the Staphylococcus aureus family. It will also include a monitoring, management and display system for data and alerts.

The current problem with cleaning products is that pathogens’ antimicrobial resistance makes disinfectant solutions less effective Stronger disinfectants such as peracetic acid must therefore be used, though it causes long-term damage to surfaces and cannot be included in daily cleaning protocols in healthcare facilities. The solution proposed by NOSOSENS has a high biocidal potential, but is biobased and biodegradable, making it less aggressive and more environmentally friendly.

Both innovations will be tested at Hospital General Universitario de Valencia, which will be equipped with a portable, easy-to-use early detection system for healthcare personnel to test for this type of bacteria, as well as an effective and sustainable pathogen elimination system for surgical elements and areas. Synergies with the sensorization platform will optimize disinfection processes for safety against hospital-acquired infections. This system will make it possible to trace and control the infectious agent and take rapid action to eliminate surface colonization, as necessary, thus minimizing the risks associated with hospital stays.

SourceAIMPLAS

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution